Recent Updates
Recently added Catalysts

AZD0585

Phase 3

Hypertriglyceridemia | Small molecule | Other |AstraZeneca PLC|Last Updated: Oct 1, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment383
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02463071AZD0585 Phase III Long-term Study in JapanPHASE3 COMPLETED 383Jun 10, 2015Mar 11, 2017Oct 1, 201826 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides
From baseline to Week12

To demonstrate the efficacy of AZD0585 2 g and 4 g compared to placebo (corn oil) in Japanese patients with hypertriglyceridemia.

Safety of AZD0585 by Assessment of Adverse Events in Patients
From baseline to Week52

To evaluate the long-term (up to 52 weeks) safety of AZD0585 in Japanese patients with hypertriglyceridemia.

Secondary Endpoints
Efficacy of AZD0585 by Assessment of Percent Change in Serum Lipid Profile
From baseline to Week12
Efficacy of AZD0585 by Assessment of Percent Changes in Plasma Fatty Acids Profile.
From baseline to Week12
Efficacy of AZD0585 by Assessment of Percent Changes in Apolipoproteins Profile
From baseline to Week12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AZD0585 2g groupEXPERIMENTALAZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
AZD0585 4g groupEXPERIMENTALAZD0585 1g × 4 capsules once daily
Placebo control groupPLACEBO_COMPARATORAZD0585 placebo 1g × 4 capsules once daily
Interventions
NameTypeDescription
AZD0585DRUG1g soft capsule
AZD0585 placeboDRUG1g soft capsule
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 130 Years
SexALL
Healthy VolunteersNo
Study Sites26

Key Inclusion Criteria: * Japanese men or women, ≥20 years of age. * Subjects must meet all of the following criteria; 1. Fasting triglyceride level: average of Visit 2 and Visit 3 must be in the range 150 - 499 mg/dL 2. %TG change between Visit 2 and Visit 3 must be within 30% 3. %LDL-C cha...

Countries:Japan
Unlock Eligibility Criteria